Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$3.36 -3.3%	$3.56	$2.45 ▼ $4.14	$266.25M	0.25	382,791 shs	72,227 shs
BYSI BeyondSpring	$1.74 -3.6%	$2.12	$0.98 ▼ $3.44	$69.97M	0.26	35,555 shs	8,090 shs
GLUE Monte Rosa Therapeutics	$4.81 -0.5%	$4.94	$3.50 ▼ $12.40	$296.76M	1.42	589,685 shs	303,217 shs
NGNE Neurogene	$18.66 -1.0%	$20.37	$6.88 ▼ $74.49	$264.27M	1.69	222,345 shs	71,010 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	-3.61%	-1.70%	-8.68%	+16.44%	-8.68%
BYSI BeyondSpring	-1.10%	+2.27%	-10.45%	+3.75%	-9.09%
GLUE Monte Rosa Therapeutics	+3.43%	+7.33%	-8.17%	+16.67%	-23.70%
NGNE Neurogene	-4.32%	-4.61%	-10.29%	+9.47%	-47.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVIR Atea Pharmaceuticals	2.4577 of 5 stars	3.3	0.0	0.0	0.0	3.3	2.5	1.3
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	2.8019 of 5 stars	3.3	1.0	0.0	0.0	2.7	1.7	1.9
NGNE Neurogene	2.346 of 5 stars	3.4	0.0	0.0	0.0	3.4	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	78.84% Upside
BYSI BeyondSpring	0.00	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	2.67	Moderate Buy	$15.33	219.11% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	147.41% Upside

Current Analyst Ratings Breakdown

Latest BYSI, GLUE, AVIR, and NGNE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$4.59 per share	N/A
BYSI BeyondSpring	$1.75M	39.98	N/A	N/A	($0.44) per share	-3.94
GLUE Monte Rosa Therapeutics	$75.62M	3.92	N/A	N/A	$4.34 per share	1.11
NGNE Neurogene	$930K	286.32	N/A	N/A	$19.15 per share	0.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$168.38M	-$1.61	N/A	N/A	N/A	N/A	-32.55%	-30.47%	11/6/2025 (Estimated)
BYSI BeyondSpring	-$11.12M	N/A	0.00	∞	N/A	N/A	N/A	N/A	11/6/2025 (Estimated)
GLUE Monte Rosa Therapeutics	-$72.70M	$0.36	13.35	N/A	N/A	13.58%	9.95%	6.42%	11/6/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.31	N/A	N/A	N/A	N/A	-33.33%	-30.34%	11/17/2025 (Estimated)

Latest BYSI, GLUE, AVIR, and NGNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	BYSI BeyondSpring	N/A	-$0.04	N/A	-$0.04	N/A	N/A
8/11/2025	Q2 2025	NGNE Neurogene	-$1.15	-$1.05	+$0.10	-$1.05	N/A	N/A
8/7/2025	Q2 2025	AVIR Atea Pharmaceuticals	-$0.46	-$0.44	+$0.02	-$0.44	N/A	N/A
8/7/2025	Q2 2025	GLUE Monte Rosa Therapeutics	-$0.31	-$0.15	+$0.16	-$0.15	$7.23 million	$23.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	19.17	19.17
BYSI BeyondSpring	N/A	2.19	2.19
GLUE Monte Rosa Therapeutics	N/A	7.16	7.16
NGNE Neurogene	N/A	18.07	18.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
BYSI BeyondSpring	40.29%
GLUE Monte Rosa Therapeutics	79.96%
NGNE Neurogene	52.37%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	18.10%
BYSI BeyondSpring	29.31%
GLUE Monte Rosa Therapeutics	6.90%
NGNE Neurogene	11.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	79.36 million	64.99 million	Optionable
BYSI BeyondSpring	80	40.33 million	28.51 million	Optionable
GLUE Monte Rosa Therapeutics	90	61.76 million	57.50 million	Optionable
NGNE Neurogene	90	14.27 million	12.61 million	Optionable

BYSI, GLUE, AVIR, and NGNE Headlines

Recent News About These Companies

EntryPoint Capital LLC Purchases New Position in Neurogene Inc. $NGNE

August 27 at 4:27 AM | marketbeat.com

Analysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $46.17

August 27 at 2:29 AM | americanbankingnews.com

Neurogene Inc. (NASDAQ:NGNE) Given Average Rating of "Moderate Buy" by Brokerages

August 24, 2025 | marketbeat.com

William Blair Issues Negative Outlook for Neurogene Earnings

August 16, 2025 | marketbeat.com

HC Wainwright Has Bearish Estimate for Neurogene Q3 Earnings

August 16, 2025 | marketbeat.com

Q3 Earnings Estimate for Neurogene Issued By Leerink Partnrs

August 16, 2025 | marketbeat.com

Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome

August 14, 2025 | theglobeandmail.com

Neurogene (NASDAQ:NGNE) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS

August 12, 2025 | marketbeat.com

Neurogene Inc. Reports Increased Losses Amid R&D Focus

August 11, 2025 | tipranks.com

Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates

August 11, 2025 | businesswire.com

Blair William & Co. IL Increases Stock Position in Neurogene Inc. (NASDAQ:NGNE)

August 10, 2025 | marketbeat.com

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 8, 2025 | businesswire.com

Raiffeisen Bank International AG Has $351,000 Stake in Neurogene Inc. (NASDAQ:NGNE)

August 7, 2025 | marketbeat.com

Neurogene (NGNE) to Release Earnings on Friday

August 1, 2025 | marketbeat.com

Bullish Neurogene Insiders Loaded Up On US$1.46m Of Stock

July 30, 2025 | finance.yahoo.com

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 5, 2025 | morningstar.comM

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

July 5, 2025 | businesswire.com

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 3, 2025 | businesswire.com

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - Morningstar

July 2, 2025 | morningstar.comM

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - Business Wire

July 2, 2025 | businesswire.com

Stifel maintient sa recommandation d’achat sur l’action Neurogene

July 2, 2025 | fr.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI, GLUE, AVIR, and NGNE Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$3.36 -0.12 (-3.31%)

As of 03:41 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

BeyondSpring NASDAQ:BYSI

$1.74 -0.07 (-3.61%)

As of 03:35 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Monte Rosa Therapeutics NASDAQ:GLUE

$4.80 -0.03 (-0.52%)

As of 03:40 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Neurogene NASDAQ:NGNE

$18.66 -0.18 (-0.96%)

As of 03:40 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time